TriSalus Life Sciences (TLSI) Receivables - Net (2022 - 2026)

TriSalus Life Sciences' Receivables - Net history runs 5 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• On a quarterly basis, Receivables - Net fell 4.36% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 4.36% decrease from a year earlier, with the FY2025 full-year figure at $6.6 million, up 28.59% from the prior year.
• Receivables - Net declined to $5.2 million in Q1 2026 per TLSI's latest filing, from $6.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $6.6 million in Q4 2025 and bottomed at $1.6 million in Q4 2022.
• The 5-year median for Receivables - Net is $5.0 million (2024), against an average of $4.6 million.
• Across the five-year window, Receivables - Net jumped 131.21% in 2023 and dropped 4.36% in 2026, its largest moves.
• Year by year, Receivables - Net stood at $1.6 million in 2022, then soared by 131.21% to $3.6 million in 2023, then soared by 41.67% to $5.1 million in 2024, then gained by 28.59% to $6.6 million in 2025, then decreased by 20.48% to $5.2 million in 2026.
• Per Business Quant, the three latest TLSI Receivables - Net figures stand at $5.2 million (Q1 2026), $6.6 million (Q4 2025), and $5.0 million (Q3 2025).